Pennington: ZyVet Animal Health, a generic pharmaceuticals company for animals, a wholly owned subsidiary of Zydus Pharmaceuticals (USA) Inc., itself a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, has released the FDA-approved generic of phenylpropanolamine hydrochloride tablets, a treatment for managing urinary incontinence in dogs, in the United States.
Phenylpropanolamine hydrochloride is commonly prescribed to treat urinary incontinence in dogs due to urethral sphincter hypotonus. Often seen in spayed females and aging dogs, urethral sphincter hypotonus can lead to frustrating and embarrassing accidents.
As per the release, ZyVet’s generic provides dependable symptom relief while supporting stronger long-term client compliance. Available in multiple strengths to support precise dosing, the product is designed with the needs of both veterinary teams and pet owners in mind.
Speaking on this development, Punit Patel, President and CEO, Zydus Americas, said “Urinary incontinence affects quality of life for both pets and their families. Our phenylpropanolamine hydrochloride tablets deliver on both clinical reliability and affordability, enabling veterinarians to confidently treat more patients and maintain client compliance. We’re proud to offer an option that removes cost as a barrier to compassionate care. With each launch, we reinforce that innovation doesn’t need to come with a premium price tag – and that every pet should have access to high-quality treatment options.”
Today, fewer than 20% of FDA-approved animal drugs have a generic version, highlighting the continued need for affordable veterinary therapies.
